Literature DB >> 24685277

Effects of fingolimod in relapsing-remitting multiple sclerosis.

Per Soelberg Sorensen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24685277     DOI： 10.1016/S1474-4422(14)70067-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

1.  Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Authors:  Saeid Sadeghi Joni; Masoumeh Cheshmavar; Pouria Shoureshi; Zohreh Zamani; Niusha Taoosi; Morteza Akbari; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-06-15

Review 2.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

3.  Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients.

Authors:  Mehrdad Farrokhi; Ali Amani Beni; Masoud Etemadifar; Ali Rezaei; Leah Rivard; Aryan Rafiee Zadeh; Nahid Sedaghat; Milad Ghadimi
Journal:  Int J Prev Med       Date:  2015-12-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.